Myeloma Progress and Where We're Headed Next with Robert Orlowski, MD, PhD, MD Anderson Cancer Center

Name: Myeloma Progress and Where We're Headed Next with Robert Orlowski, MD, PhD, MD Anderson Cancer Center
Start: 2017-01-05T11:00:00-07:00
End: 2017-01-05T12:00:00-07:00

Myeloma Progress and Where We're Headed Next with Robert Orlowski, MD, PhD, MD Anderson Cancer Center

Podcast

Jan 05, 2017 / 11:00AM MST

Listen to Podcast

Event Description

Robert Z. Orlowski, MD, PhD MD Anderson Cancer Center Interview Date: January 5, 2017

The year 2017 promises to be another exciting one in multiple myeloma. Dr. Robert Orlowski shares key developments from last year and what we have to look forward to in the coming year. He describes several important advances last year: the further approvals of elotuzumab and daratumumab and the latest on bone strengtheners - that denosumab may be better than Zometa. He also shares the new approaches in smoldering myeloma to prevent progression, the latest on stem cell transplants and the use of minimal residual disease (MRD) as a useful measurement. He shares a new tool for patients with renal failure that can improve their function in order to avoid dialysis and where were are headed with the broad class of immunotherapy approaches. Dr. Orlowski provides an impressive, overarching view of what we can look forward to in the management and treatment of multiple myeloma in the coming year.

Thanks to our episode sponsor

Schedule & Agenda

Event panelist Dr. Robert Orlowski & Jenny Ahlstrom

11:00 AM

Discussion

Dr. Robert Orlowski & Jenny Ahlstrom

11:00 AM

Discussion

Dr. Robert Orlowski & Jenny Ahlstrom

Speakers & Moderators

Robert Orlowski, MD, PhD

Robert Z. Orlowski, M.D., Ph.D., is Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, where he is board-certified in medical oncology. Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in Internal Medicine at Barnes Hospital at the Washington University in St. Louis School of Medicine. After his fellowships in Hematology and Medical Oncology at John Hopkins Sidney Kimmel Comprehensive Cancer Center, he joined the faculty at University of North Carolina in Chapel Hill. Following that, Dr. Orlowski accepted a position at The University of Texas MD Anderson Cancer Center in 2007 to lead the Myeloma Section in the Department of Lymphoma/Myeloma. His research interests include pathobiology of, novel therapeutic targets and mechanisms of drug resistance in myeloma which are documented in hundreds of scientific articles, book chapters, and presentations at conferences. Dr. Orlowski is an investigator on numerous clinical trials, and appointed Myeloma Committee Chair for SWOG.

Read Bio

Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio